- Home
- AGEN
AGEN
Agenus Inc.
as 06-10-2025 4:00pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 87.7M | IPO Year: | 2000 |
| Target Price: | $13.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $18.74 | Next Earning Date: | 05-12-2025 |
| Revenue: | $99,524,000 | Revenue Growth: | -38.34% |
| Revenue Growth (this year): | 14.49% | Revenue Growth (next year): | -4.70% |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Agenus Shares Rise After Upgrade From HC Wainwright
Zacks
7 days ago
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade
Pharmaceutical Technology
7 days ago
Agenus and Zydus sign agreements for botensilimab and balstilimab
MT Newswires
7 days ago
HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target
MT Newswires
7 days ago
Agenus to Sell US Manufacturing Facilities to Zydus Lifesciences
Business Wire
8 days ago
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
Business Wire
12 days ago
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
Zacks
23 days ago
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
Compare AGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.